Detalle Publicación

ARTÍCULO

A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib

Autores: de la Torre Aláez, Manuel Antonio; Buades Mateu, Juan Sebastián; de la Rosa Fernández Pacheco, Pedro Antonio; Lue, Alberto; Bustamante, Francisco J; Serrano, María T.; Testillano, Milagros; Lorente, Sara; Arenas, Juan I.; Gil, Cristina; Iñarrairaegui Bastarrica, Mercedes; Sangro Gómez-Acebo, Bruno Carlos
Título de la revista: LIVER INTERNATIONAL
ISSN: 1478-3223
Volumen: 36
Número: 8
Páginas: 1206-1212
Fecha de publicación: 2016
Resumen:
After a median follow-up of 6 months, 60 deaths had occurred: 38 and 22 in SOR and RE groups respectively. Median survival was 6.7 months (95%CI 5.2-8.1 months) for the entire cohort, and 8.8 months (95%CI 1.8-15.8) in the RE group and 5.4 months (95%CI 2.7-8.1) in the SOR group (P = 0.047). The difference in survival was still statistically significant when 13 patients in the RE group who started SOR after a median time of 8 months were censored from the analysis. CONCLUSIONS: In a cohort of patients with HCC and PVI treatment with RE was associated with a more prolonged survival compared with SOR.
DOI: https://doi.org/10.1111/liv.13098
Impacto:
Google Scholar